|Bid||0.00 x 1100|
|Ask||0.00 x 1200|
|Day's range||152.57 - 158.52|
|52-week range||112.07 - 305.21|
|Beta (5Y monthly)||0.97|
|PE ratio (TTM)||38.10|
|Earnings date||25 Apr 2022 - 29 Apr 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||23 Nov 2012|
|1y target est||145.75|
Masimo's (MASI) robust product shipments and strength in its healthcare business drive its Q2 sales.
Joining me today are chairman and CEO, Joe Kiani; and executive vice president and chief financial officer, Micah Young. This call will contain forward-looking statements, which reflect management's current judgment, including certain of our expectations regarding fiscal year 2022 financial performance.
Masimo (MASI) delivered earnings and revenue surprises of 13.45% and 4.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?